CALC CalciMedica, Inc. Insider Trading

Director Fred A Middleton purchases 248,972 shares of CALC at $0.80; stock 88.6% below 52-week high

Director Fred A Middleton purchased 248,972 shares of CalciMedica at $0.80 on 2026-06-25, increasing his holdings by +30.6% to 1.06M shares total. At the current price of $0.82, the stock trades 88.6% below its 52-week high of $7.20, though it has risen +44.1% over the prior 90 days and +10.1% over the prior 30 days. His prior trades at CALC show mixed outcomes: 1 of 5 prior buys achieved positive 90-day returns, suggesting limited track record of well-timed entry timing at this ticker. The company reported net income of $4,976,000.00, though it was unprofitable over its most recent full fiscal year, creating context of elevated execution risk despite near-term price momentum.

CalciMedica CBO Roberts purchases 2,500 shares at $3.07; 5 buys in 10 days as stock rallies 95.8% in 90 days

Roberts Eric W, Chief Business Officer of CalciMedica, purchased 2,500 shares at $3.07 on 2025-09-18, adding to his holdings of 84,150 shares post-transaction. This transaction is the fifth open-market buy by this insider in a 10-day window (2025-08-28 through 2025-09-18), with prior purchases on 2025-09-15, 2025-09-12, 2025-09-09, and 2025-08-29. The stock price has appreciated 95.8% over the trailing 90 days and currently trades at $3.23, up 16.2% over the last 30 days, though it remains 35.3% below its 52-week high of $4.99. Across his broader cross-ticker history, Roberts has executed 20 prior open-market buys with an average 90-day return of +45.2% and a 60.00% win rate. However, these five concurrent purchases at CalciMedica remain too recent to evaluate measurable 90-day outcomes. The company posted negative net income of $-5,956,000.00 and carries a market cap of $45,130,131.71, indicating a small, unprofitable enterprise. The clustering of five discretionary purchases over 10 days during a period of strong stock appreciation warrants monitoring to determine whether outcomes align with the insider's historical cross-ticker success rate.

Chief Business Officer Eric W Roberts buys 3,400 shares at $2.68 after four recent buys in same week

Roberts Eric W (Chief Business Officer) purchased 3,400 shares of CALC at $2.68 on 2025-09-15, bringing his holdings to 81,650 shares, in the context of five accumulated buy transactions at this ticker within the past month. The stock is currently trading at $3.20, representing a gain of +19.4% from his transaction price, though the company reported a negative net income of $-6.0M for its most recent fiscal year. His cross-ticker track record shows a 50.00% 90-day win rate with average returns of +37.0%, but none of his five recent CALC purchases have yet reached measurable outcome thresholds. The rapid accumulation pattern warrants observation of whether this reflects ordinary capital deployment by a senior executive or signals a data point worth monitoring as the year progresses.

CALC CBO Roberts buys 5,000 shares at $3.12 on 2025-09-12; stock now $2.85, -42.9% from 52-week high

Roberts Eric W, Chief Business Officer, purchased 5,000 shares at $3.12 on 2025-09-12, raising his holdings to 78,250 shares (+6.8% increase). The purchase occurred at a price notably above the current market price of $2.85, and well above the company's lowest point in the 52-week range. CalciMedica is currently unprofitable with net income of $-5,956,000.00 over the most recent full fiscal year, with a market cap of $39,820,704.45. The stock is down 42.9% from its 52-week high and down 2.1% over the past 30 days, though it has gained 68.6% over 90 days. Roberts' cross-ticker track record shows prior buys averaging +20.2% return at 30 days and +37.0% at 90 days with a 50% win rate, but his five prior purchases at CALC remain too recent to measure outcomes; all were made between 2025-08-21 and 2025-09-15.

Chief Business Officer Roberts buys 2,343 shares at $3.15 amid 5 consecutive purchases and -35.3% drawdown from 52-week high

Roberts Eric W (Chief Business Officer) purchased 2,343 shares of CALC at $3.15 on 2025-09-09, extending a rapid buying sequence: he has now made 5 separate open-market purchases in 11 days (August 19–29 and September 9). This purchase occurred while the stock trades at -35.3% from its 52-week high of $5.30, despite a strong 30-day rally of +38.3% and 90-day surge of +99.4%. The company remains unprofitable with net income of $-5,956,000.00 on a market cap of $47,924,567.11. Notably, outcomes from his four prior CALC purchases (August 19–29) are not yet measurable at 30 or 90 days, preventing any assessment of whether this insider's repeated buying at declining valuations reflects informational advantage or simply mechanical accumulation during a drawdown phase. His cross-ticker track record shows an average 90d return of +30.0% across 20 prior buys, but CALC represents a new pattern: five trades compressed into two weeks at a loss-making company.

CALC CBO Roberts purchases 10,000 shares (10.0K) for $28,531.60 in 2 transactions; 4th buy in 8 days.

Chief Business Officer Eric W Roberts made 2 separate purchases totaling 10,000 shares for $28,531.60 at a blended average price of $2.85 on 2025-08-28 and 2025-08-29, bringing his post-transaction holdings to 70,907 shares (70.9K shares), a 16.4% increase from 60,907 shares. The current price of $3.10 is 41.5% below the 52-week high and 80.8% above its 90-day low, suggesting modest recovery from depressed levels. More notable is the pattern: Roberts has executed 4 separate open-market buys at CALC within 8 days (2025-08-15, 2025-08-19, 2025-08-20, and 2025-08-21), with this filing capturing his 2 most recent transactions. None of his 5 prior trades at this ticker have measurable 90-day outcomes yet, and his cross-ticker track record shows a 42.86% 90-day win rate with an average 90-day return of -1.6%, indicating his prior buy decisions have not reliably outperformed. The company remains unprofitable (net income $-6.0M) on a $43.3M market cap, adding context to the timing and conviction behind the accumulation pattern.

CALC Chief Business Officer Roberts buys 3,508 shares at $2.79 (4th buy in 7 days); stock -47.4% from 52-week high, company unprofitable (-$6.0M net income).

Roberts Eric W, Chief Business Officer of CalciMedica, purchased 3,508 shares at $2.79 on 2025-08-21, extending a buying pattern that includes 3 prior purchases within the preceding 7 days at prices ranging from $2.79 to $3.50. The stock is currently trading -47.4% from its 52-week high of $5.30 and declined -26.6% over the past 30 days, though it has gained 58.5% over 90 days. CalciMedica reported net income of -$6.0M over its most recent full fiscal year, placing the company firmly in loss-making territory with a market cap of $39.0M. Roberts' cross-ticker buying history shows a 50% win rate at 90 days with an average 90-day return of +8.5%, but his prior trades specifically at CALC have not yet reached measurable 90-day outcomes, with the earliest same-ticker purchase (2025-07-21) showing a -18.4% return through 30 days. The concentration of purchases in a narrow timeframe amid significant price depreciation and unprofitability merits investor scrutiny.

CMO Hebbar Sudarshan purchases 9,563 shares of CALC at $2.82 on 2025-08-19, expanding stake by 18.4% amid -26.2% 30-day decline from peak.

Hebbar Sudarshan, Chief Medical Officer of CalciMedica, executed a buy of 9,563 shares at $2.82 on 2025-08-19, the third purchase within five days and expanding his post-transaction holdings to 61.5K shares (18.4% increase). The purchase occurs with the stock 47.4% below its 52-week high and down 26.2% over the prior 30 days, yet his same-ticker history shows 2 of 2 prior measurable buys were well-timed at the 90-day mark (43.5% and 99.3% gains 30-days out; 126.4% and 18.5% 90-days out). The company remains unprofitable with net income of -$6.0M, limiting the informational value of fundamental health, and the stock has risen 55.0% over 90 days despite the recent pullback. The repeated purchases in rapid succession and positive history at this specific ticker warrant tracking of whether this accumulation aligns with operational recovery or asset positioning.

CBO Roberts buys 3,000 shares at $2.74–$2.79 avg; CALC down 47.4% from high, but insider shows mixed same-ticker timing.

Roberts Eric W, Chief Business Officer of CalciMedica (CALC), purchased 3,000 shares across 2 transactions on 2025-08-19 and 2025-08-20 for a blended average of $2.74, increasing his holdings by 1.7% to 179,706 shares. The stock is currently down 47.4% from its 52-week high and down 26.2% over 30 days, creating a low-price environment for acquisition. However, Roberts' timing record at CALC is not encouraging: his prior 5 trades at this ticker show mostly negative 30-day returns (-26.1% and -18.4% on his last two buys), with only 1 trade showing modest positive return (+1.0%). His cross-ticker track record (20 prior buys) shows stronger performance (avg 90d return +21.0%, 55.56% win rate), but those results do not transfer to this specific holding. The company is unprofitable with a net loss of $-5,956,000.00 over the most recent full fiscal year.

CALC Chief Business Officer Eric W Roberts bought 5,076 shares at $2.90 on 2025-08-15, raising holdings to 54,399 shares (+10.3%).

Roberts Eric W, Chief Business Officer, purchased 5,076 shares at $2.90 on 2025-08-15, expanding his holdings by 10.3% to 54,399 shares post-transaction. The transaction occurs while CalciMedica's stock trades at $2.78 current price, down 47.6% from its 52-week high of $5.30 and down 7.6% over the past 30 days, despite a 90-day rally of 58.9%. Notably, this buy follows a pattern of five consecutive purchases at CALC within the past month (2025-07-14 through 2025-08-19), suggesting continued accumulation during a period of volatility; however, same-ticker timing outcomes remain limited, with only one prior CALC buy showing a measurable 30-day result (-2.8%), while the broader cross-ticker track record shows 60% 90-day win rate across 20 prior buys averaging +30.8% returns. The company's fundamental position—unprofitable with net income of $-5,956,000.00 and market cap of $38,842,652.06—adds material context to interpreter assessment of whether accumulation reflects conviction or obligatory vesting patterns.